Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations

JAMA. 2020 Jan 28;323(4):372-374. doi: 10.1001/jama.2019.18587.

Abstract

This pharmacoepidemiology study uses Medicaid data to estimate associations between first-trimester use of intravenous ondansetron and risk of cardiac malformations and oral cleft in children of exposed mothers.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Abnormalities, Drug-Induced*
  • Administration, Oral
  • Adult
  • Antiemetics / administration & dosage
  • Antiemetics / adverse effects*
  • Cleft Lip / chemically induced
  • Cleft Palate / chemically induced
  • Female
  • Follow-Up Studies
  • Heart Defects, Congenital / chemically induced
  • Humans
  • Injections, Intravenous
  • Nausea / drug therapy
  • Ondansetron / administration & dosage
  • Ondansetron / adverse effects*
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Pregnancy Trimester, First
  • Risk

Substances

  • Antiemetics
  • Ondansetron